* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Tuesday, September 9, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    Jobs roundup: September 2025 | Blizzard Entertainment appoints Walter Kong SVP of live games/mobile development – GamesIndustry.biz

    Blizzard Entertainment Names Walter Kong as SVP of Live Games and Mobile Development in September 2025 Jobs Update

    Monumental Sports & Entertainment Sets Corporate Direction at Nasdaq – PR Newswire

    Monumental Sports & Entertainment Reveals Bold New Corporate Vision at Nasdaq

    The Secret to What Made ‘CarJack’ Work on As the World Turns – yahoo.com

    The Surprising Secret Behind ‘CarJack’s’ Success on As the World Turns

    Victor Garber on his viral “And Just Like That” toilet scene: ‘I was delighted to be doing something ridiculous’ (exclusive) – yahoo.com

    Victor Garber on his viral “And Just Like That” toilet scene: ‘I was delighted to be doing something ridiculous’ (exclusive) – yahoo.com

    Pendulum Announce Homecoming 2026 Australian Tour – yahoo.com

    Pendulum Announces Thrilling Homecoming Tour Across Australia in 2026

    ITV Studios Launches New Entertainment Label – Global Bulletin – IMDb

    ITV Studios Unveils Exciting New Entertainment Label

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    ASE Technology (ASX) Hits Record High on AI Fuel – uk.finance.yahoo.com

    ASE Technology Rockets to New Heights Driven by Game-Changing AI Breakthroughs

    Tri-Counties Bank marks 50 years of growth with focus on technology and personal service – thebusinessjournal.com

    Tri-Counties Bank Celebrates 50 Years of Growth Driven by Technology and Personal Service

    AI will reshape internet, create jobs in West Virginia says High Technology Foundation’s Estep – WV News

    How AI Is Set to Transform the Internet and Boost Job Growth in West Virginia

    Industry partner provides Ferris State Plastics Engineering Technology students with state-of-the-art equipment to gain in-demand skills – Ferris State University

    Industry Partner Equips Ferris State Plastics Engineering Students with Cutting-Edge Technology to Boost In-Demand Skills

    Health Technology Ecosystem – Centers for Medicare & Medicaid Services | CMS (.gov)

    Discover the Future of Health Technology: Innovations Revolutionizing Patient Care

    Coherent Joins LLNL’s STARFIRE Diode Technology Working Group to Advance Inertial Fusion Energy – GlobeNewswire

    Coherent Partners with LLNL’s STARFIRE Team to Drive Breakthroughs in Inertial Fusion Energy

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    Jobs roundup: September 2025 | Blizzard Entertainment appoints Walter Kong SVP of live games/mobile development – GamesIndustry.biz

    Blizzard Entertainment Names Walter Kong as SVP of Live Games and Mobile Development in September 2025 Jobs Update

    Monumental Sports & Entertainment Sets Corporate Direction at Nasdaq – PR Newswire

    Monumental Sports & Entertainment Reveals Bold New Corporate Vision at Nasdaq

    The Secret to What Made ‘CarJack’ Work on As the World Turns – yahoo.com

    The Surprising Secret Behind ‘CarJack’s’ Success on As the World Turns

    Victor Garber on his viral “And Just Like That” toilet scene: ‘I was delighted to be doing something ridiculous’ (exclusive) – yahoo.com

    Victor Garber on his viral “And Just Like That” toilet scene: ‘I was delighted to be doing something ridiculous’ (exclusive) – yahoo.com

    Pendulum Announce Homecoming 2026 Australian Tour – yahoo.com

    Pendulum Announces Thrilling Homecoming Tour Across Australia in 2026

    ITV Studios Launches New Entertainment Label – Global Bulletin – IMDb

    ITV Studios Unveils Exciting New Entertainment Label

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    ASE Technology (ASX) Hits Record High on AI Fuel – uk.finance.yahoo.com

    ASE Technology Rockets to New Heights Driven by Game-Changing AI Breakthroughs

    Tri-Counties Bank marks 50 years of growth with focus on technology and personal service – thebusinessjournal.com

    Tri-Counties Bank Celebrates 50 Years of Growth Driven by Technology and Personal Service

    AI will reshape internet, create jobs in West Virginia says High Technology Foundation’s Estep – WV News

    How AI Is Set to Transform the Internet and Boost Job Growth in West Virginia

    Industry partner provides Ferris State Plastics Engineering Technology students with state-of-the-art equipment to gain in-demand skills – Ferris State University

    Industry Partner Equips Ferris State Plastics Engineering Students with Cutting-Edge Technology to Boost In-Demand Skills

    Health Technology Ecosystem – Centers for Medicare & Medicaid Services | CMS (.gov)

    Discover the Future of Health Technology: Innovations Revolutionizing Patient Care

    Coherent Joins LLNL’s STARFIRE Diode Technology Working Group to Advance Inertial Fusion Energy – GlobeNewswire

    Coherent Partners with LLNL’s STARFIRE Team to Drive Breakthroughs in Inertial Fusion Energy

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Breast Cancer

July 1, 2024
in Health
Ribociclib Reduces Risk of Recurrence for High-Risk Node-Negative Breast Cancer
Share on FacebookShare on Twitter

The latest analysis from the phase III NATALEE trial demonstrated that adding ribociclib (Kisqali) to endocrine therapy improved rates of invasive disease-free survival (iDFS), distant recurrence-free survival, and distant disease-free survival in high-risk early breast cancer patients with node-negative disease. The findings were reported at the recent American Society of Clinical Oncology (ASCO) annual meeting.

MedPage Today brought together three expert leaders in the field for a virtual roundtable discussion: moderator Hope S. Rugo, MD, of the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, is joined by Joyce O’Shaughnessy, MD, of Baylor University Medical Center and Texas Oncology in Dallas, and Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute in Boston. This third of four exclusive episodes focuses on the updated data from the NATALEE trial.

Click here to watch the other videos from this ASCO roundtable series on breast cancer.

Following is a transcript of their remarks:

Rugo: We’ve been so excited about the monarchE data with abemaciclib (Verzenio) in early stage high-risk disease, followed shortly thereafter by the NATALEE data, which is a little less mature with a medium follow-up of about 3 months giving ribociclib for 3 years at a slightly lower dose than is approved in the metastatic setting, 400 mg. But NATALEE, in addition to changing the dose and the duration compared to what the monarchE trial did, also included a lower-risk population. They have a lot of patients with high-risk disease, but they included a group of patients who had a lower node-negative disease, but had some high-risk features. So high grade, high genomic risk score, and T2 tumors. And of course they’re interested in expanding that further.

But then there’s been a lot of questions — does it work in these lower-risk patients and how much does it need to work to make it worth it to give this drug that requires blood monitoring, liver enzyme monitoring, and causes a little thinning of the hair and fatigue for 3 years in patients who finished therapy? Now our node-negative patients are going to have finished less therapy. We don’t give them more intensive chemo. But what was your take. Denise Yardley did a lovely job of presenting in 6 minutes. It was the new rapid orals here in early-stage disease, but really interesting data.

Tolaney: Yeah, I mean, I was actually really looking forward to this because that’s been one of the big questions in my head. Obviously monarchE was a fully node-positive population. We didn’t have any patients who’d been exposed to [abemaciclib] in a node-negative setting. And here they selected the node-negatives, right? They had to be over 2 cm if you’re a node-negative, you had to be either high-grade or if you’re intermediate-grade, you had to have another high-risk feature like high Ki67 or high genomic risk score. So you picked people who had more risk than maybe the average node-negative patient, but they did show about a 3% benefit in terms of invasive disease-free survival with the majority of the events being distant events. The number of events here is not large. And so I do think we have to keep that in mind.

The follow-up is still short. And so I think it’s saying that there’s benefit, and I think the question is very much in line with what you had said up front, is it worth it? It’s 3 years of therapy overall. Right now the iDFS is over 90% in both arms. Are we really having a large enough impact to make it worth it? And I think this is a tough one. I think we’re going to weigh it based on how risky is that node-negative patient, right? Is it a larger node-negative cancer that’s high-grade, high-Oncotype. That’s someone I would think about it in.

But in my mind, this is a discussion with the patient because they have to be open to taking an extra drug for 3 years, as you point out, does have some impact because they are coming in and out of clinic a lot more than they would be if they weren’t on these agents. But definitely I think worth the discussion for the higher-risk patients.

Rugo: Yeah, I mean, of course we don’t have ribociclib approved yet, but we expect that we will see an approval and they only had 3 years of follow-up. To me, and maybe I think for all of us, it might’ve been a little more impressive because with a node-negative group where you selected them for early recurrence, they did see a difference. But 3 years is just at the end of treatment. So now what we want to see is the same kind of carryover effect.

And also for both drugs, what happens to the dormancy, the later recurrence risks? So far, the patients that have been included are not the ones who are highest for later recurrence. They were selected for higher recurrence risk. So the planned WIDER trial that would include a lower-risk population — maybe for somebody else’s career, I’m thinking it’s going to take 10 years — might show some benefit in that population with carryover.

But Joyce, what will you do with that data come next week? I mean, if you had ribociclib, would you give it to those patients?

O’Shaughnessy: Yes, everybody who was eligible for NATALEE, I would. Because as I think about what’s the risk overall for our patients with the T2 or T3, N0, and as Sarah said, if they’re T2, high recurrence score or high MammaPrint, those are high-risk women. Or grade 3, the Ki67, 20% or above, that’s a mixed population. If you start getting 30%, 40%, 50%, now you’re really getting high risk. But 20%, 25% isn’t that high risk. So that’s a mixed bag.

But overall, those are high-risk patients and chemotherapy doesn’t work great in ER [estrogen receptor]-positive breast cancer. Endocrine therapy, it was obviously effective. But I think these patients, this node-negative patient population, has a residual risk of 20-plus% over their lifetime. That’s high, one in five to me, so I’m going to talk to each and every patient about it.

One thing that’s good that they needed to get down on the dose to 200; it did not lose efficacy. And so that becomes, and then they could get out to the every-3-monthly follow-up before too long. You know what I mean? So I’m going to offer it to everybody.

Tolaney: I think, I don’t know. I feel like I’m not quite ready to offer it to everyone. I think these drugs are highly effective drugs, but I think we have to weigh risk-benefit, and we still do see elevated liver enzymes, neutropenia, needing to come back and forth from clinic. And so I think it has an impact on patient’s quality of life. And so I think I would definitely offer it to maybe the higher-risk of the node-negative, of the enriched high-risk patients already and definitely have a discussion about it.

But I think once I had longer follow-up, maybe then I would turn to offering it to more patients. But it is a smaller subset of the trial and that’s what makes me feel quite not as confident.

Rugo: And it is quite, I mean, it is a small subset because they amplified the high-risk group once they saw the monarchE results, which turned out to be a very clever move. So it’s really interesting. So hopefully we’ll see.

They’re reformulating the pill now and hopefully we’ll see some indication about approval or not later this year. And then the WIDER trial, which will look at a lower-risk population and is not randomized — it’s enrolling quite a number of patients, several thousand — will also hopefully open this fall. So I think there’ll be lots of opportunities to learn more. And I think that the monitoring for toxicity in particular, the liver function in addition to the neutropenia we’re all used to managing, is really important.

author['full_name']

Greg Laub is the Senior Director of Video and currently leads the video and podcast production teams. Follow

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/meetingcoverage/ascoexpertroundtablebreastca/110899

Tags: healthReducesRibociclib
Previous Post

Life expectancy in Australia has fallen for the first time in about 30 years

Next Post

CAH Drug Under Review; Gender-Affirming Surgery in Kids; CGMs for Non-Diabetics

The making of an ecological disaster in the Nicobar – The Hindu

How Human Actions Sparked an Ecological Disaster in the Nicobar Islands

September 9, 2025
Science is under siege from weaponised disinformation – posing a threat to human civilisation – The Guardian

Science is under siege from weaponised disinformation – posing a threat to human civilisation – The Guardian

September 9, 2025
Two Harvard Scientists Finalists for Blavatnik Award – Harvard Gazette

Two Harvard Scientists Advance as Finalists for Prestigious Blavatnik Award

September 9, 2025
Why group chats drain you more than actual conversations — even when you hardly say a word – VegOut

Why Group Chats Exhaust You More Than Real Conversations-Even When You Say Almost Nothing

September 9, 2025
ASE Technology (ASX) Hits Record High on AI Fuel – uk.finance.yahoo.com

ASE Technology Rockets to New Heights Driven by Game-Changing AI Breakthroughs

September 9, 2025
Mike White chats live with high school sports fans ahead of Week 3 – Pittsburgh Post-Gazette

Mike White chats live with high school sports fans ahead of Week 3 – Pittsburgh Post-Gazette

September 9, 2025
Grace for the World: Watch the Live Concert from Vatican City! – Disney Plus

Grace for the World: Watch the Live Concert from Vatican City! – Disney Plus

September 9, 2025
22 Timeless Money Maxims That Hold up in the Current Economy – Money Talks News

22 Timeless Money Maxims That Still Work in Today’s Economy

September 9, 2025
Jobs roundup: September 2025 | Blizzard Entertainment appoints Walter Kong SVP of live games/mobile development – GamesIndustry.biz

Blizzard Entertainment Names Walter Kong as SVP of Live Games and Mobile Development in September 2025 Jobs Update

September 9, 2025
State Health Care Spending Growth Trends Point to Need for Policy Action – Milbank Memorial Fund

Soaring State Health Care Costs Demand Immediate Policy Solutions

September 9, 2025

Categories

Archives

September 2025
MTWTFSS
1234567
891011121314
15161718192021
22232425262728
2930 
« Aug    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (814)
  • Economy (832)
  • Entertainment (21,709)
  • General (16,943)
  • Health (9,874)
  • Lifestyle (846)
  • News (22,149)
  • People (835)
  • Politics (839)
  • Science (16,042)
  • Sports (21,332)
  • Technology (15,813)
  • World (814)

Recent News

The making of an ecological disaster in the Nicobar – The Hindu

How Human Actions Sparked an Ecological Disaster in the Nicobar Islands

September 9, 2025
Science is under siege from weaponised disinformation – posing a threat to human civilisation – The Guardian

Science is under siege from weaponised disinformation – posing a threat to human civilisation – The Guardian

September 9, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version